The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study
暂无分享,去创建一个
Cedrik M. Britten | Cécile Gouttefangeas | Marij J. P. Welters | Ton N. Schumacher | Karoline Laske | Christian Ottensmeier | S. H. van der Burg | T. Schumacher | M. Welters | K. Franken | C. Ottensmeier | C. Britten | C. Gouttefangeas | E. Verdegaal | Els M. Verdegaal | Sjoerd H. van der Burg | Satwinder Kaur Singh | Bart Tummers | Raquel Gomez | Kees L. M. C. Franken | Raquel Gomez | Karoline Laske | B. Tummers
[1] Sylvia Janetzki,et al. Harmonization of Immune Biomarker Assays for Clinical Studies , 2011, Science Translational Medicine.
[2] M. Albert,et al. Enumeration of human antigen-specific naive CD8+ T cells reveals conserved precursor frequencies. , 2010, Blood.
[3] D. Speiser,et al. Ex Vivo Analysis of Human Antigen-Specific CD8+ T-Cell Responses: Quality Assessment of Fluorescent HLA-A2 Multimer and Interferon-γ ELISPOT Assays for Patient Immune Monitoring , 2004, Journal of immunotherapy.
[4] K. Rezvani,et al. Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. , 2009, Blood.
[5] S. H. van der Burg,et al. Identification of a conserved universal Th epitope in HIV-1 reverse transcriptase that is processed and presented to HIV-specific CD4+ T cells by at least four unrelated HLA-DR molecules. , 1999, Journal of immunology.
[6] M. Perricone,et al. Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients , 2008, Journal of Translational Medicine.
[7] D. Busch,et al. Quantitation of MHC tetramer‐positive cells from whole blood: Evaluation of a single‐platform, six‐parameter flow cytometric method , 2004, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[8] A. Mackensen,et al. The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays , 2007, Cancer Immunology, Immunotherapy.
[9] D. Speiser,et al. Distinct sets of αβ TCRs confer similar recognition of tumor antigen NY-ESO-1157–165 by interacting with its central Met/Trp residues , 2008, Proceedings of the National Academy of Sciences.
[10] F. Wong,et al. Immunology of Diabetes Society T‐Cell Workshop: HLA class I tetramer‐directed epitope validation initiative T‐Cell Workshop Report—HLA Class I Tetramer Validation Initiative , 2011, Diabetes/metabolism research and reviews.
[11] P. Schrier,et al. Interleukin‐2‐induced, melanoma‐specific T cells recognize camel, an unexpected translation product of LAGE‐1 , 1999, International journal of cancer.
[12] G. Ogg,et al. Ex Vivo Staining of Metastatic Lymph Nodes by Class I Major Histocompatibility Complex Tetramers Reveals High Numbers of Antigen-experienced Tumor-specific Cytolytic T Lymphocytes , 1998, The Journal of experimental medicine.
[13] Cedrik M. Britten,et al. Response definition criteria for ELISPOT assays revisited , 2010, Cancer Immunology, Immunotherapy.
[14] B. Comin-Anduix,et al. Definition of an Immunologic Response Using the Major Histocompatibility Complex Tetramer and Enzyme-Linked Immunospot Assays , 2006, Clinical Cancer Research.
[15] L. J. Old,et al. Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond , 2010, Cancer Immunology, Immunotherapy.
[16] S. H. van der Burg,et al. Performance of serum-supplemented and serum-free media in IFNγ Elispot Assays for human T cells , 2009, Cancer Immunology, Immunotherapy.
[17] Sylvia Janetzki,et al. "MIATA"-minimal information about T cell assays. , 2009, Immunity.
[18] C. Gouttefangeas,et al. Serum is not required for ex vivo IFN-γ ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program , 2010, Cancer Immunology, Immunotherapy.
[19] P. Klenerman,et al. Ultrasensitive Detection and Phenotyping of CD4+ T Cells with Optimized HLA Class II Tetramer Staining1 , 2005, The Journal of Immunology.
[20] Cedrik M. Britten,et al. Harmonization of the intracellular cytokine staining assay , 2012, Cancer Immunology, Immunotherapy.
[21] Tak W. Mak,et al. Human T-cell receptor variable gene segment families , 1995, Immunogenetics.